Lexeo Therapeutics Financials - Benzinga

Lexeo Therapeutics Inc

LXEONASDAQ

Trade with Public

Trade with Public

$4.07

-0.01-0.25%

At close: Sep 22, 5:00 PM EST

$4.07

N/A

After Hours: 6:59 PM EST

M&A: Mantle Therapeutics Inc. announced today it will be acquired by Lexeo Therapeutics (LXEO) for $8.3M paid in cash & stock

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Lexeo Therapeutics Financials

Lexeo Therapeutics (LXEO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 50 percent increase over losses of $(0.60) per share from

Benzinga Newsdesk

PRO
Lexeo Therapeutics Q1 EPS $(0.25) Beats $(0.33) Estimate, Cash, Cash Equivalents And Investments Of $227.6M Expected To Provide Operational Runway Into 2028

Benzinga Newsdesk

PRO
Lexeo Therapeutics Q4 EPS $(0.27) Beats $(0.34) Estimate

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.34) by 21.28 percent. This is a 65.38 percent increase over losses of $(0.78) per share

Benzinga Newsdesk

PRO
Lexeo Therapeutics Q3 EPS $(0.33) Beats $(0.54) Estimate

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.78 percent. This is a 62.92 percent increase over losses of $(0.89) per share

Benzinga Newsdesk

PRO
Lexeo Therapeutics Q2 EPS $(0.60) Beats $(0.68) Estimate

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.68) by 11.76 percent. This is a 6.25 percent increase over losses of $(0.64) per share from

Benzinga Newsdesk

PRO
Lexeo Therapeutics Q1 EPS $(0.99) Misses $(0.78) Estimate

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 28.57 percent decrease over losses of $(0.77) per share

Benzinga Newsdesk